Just think Bob, your tax $$$$$$$$$$$ going to an IGNORANT doctor along with the rest of the circus crew.
Give me one tenth of that million and I can grow enough REAL healing drugs, natural healing, and we wouldn't need trials either we already know it works.
I could grow enough for all of them.
Sometimes I really shouldn't read the news. It gets to depressing.
They think their so called college education means they actually know something. They don't know anything but how to give more people man made CRAP!
Seattle scientists developing non-addictive pain drug
By Molly Shen
Published: Sep 30, 2015 at 4:30 PM PDT
SEATTLE -- Pain is a devastating health problem. And of the millions of people who suffer from chronic pain, a large percentage are soldiers, wounded in battle.
"A lot of wounded warriors and veterans are dealing with these issues. They have burn injuries, amputations. Now they've come back home and the Army needs to treat them and rehabilitate those patients. Unfortunately, one of the best tools they have are opioid drugs," said Dr. Charles Magness, CEO of Seattle biotech Kineta. "So the potential is those soldiers get home and end up becoming addicted to the drugs they're using to treat the result of their battlefield injuries."
That's why the U.S. Army is investing more than a million dollars in research happening in Kineta's South Lake Union laboratory. Kineta is developing a new class of pain medication that would treat pain without fears of addiction.
At the UW Medicine Center for Pain Relief, Dr. David Tauben has seen plenty of patients who can't work, who become depressed and isolated because of pain. "Pain is very frustrating for patient's families, disruptive for their economic activity and engagement in community," Dr. Tauben said. "I'm looking forward to some new breakthroughs."
Scientists at Kineta hope the next big breakthrough is found in the ocean. The cone snail uses venom to paralyze its prey, and a protein in that venom might also paralyze pain.
"That's what we're trying to block," said Magness. "Block the actual transmission of the pain signal. The drug does not have to get into the brain. That's why we hold out so much hope that it won't be habit forming, won't cause cognitive impact because it actually works at the site of the nerve injury."
Within the next year, Kineta hopes to move into human trials. If all goes well, the drug is still at least five years away from being on the market.
Based on my calculations, I can retire 5 years after I die.
